Pediatrix Medical (MD) Fundamental Analysis: Revenue, Earnings & Valuation

5.52 / 10

Netural

Fundamental score is 5.5/10, indicating a balanced outlook. Strengths include Revenue‑MV, Net‑income‑Revenue, and strong YoY EPS growth (basic and diluted) plus total profit growth. Weaknesses are inventory turnover efficiency, cash‑UP and cash‑MV, leading to a guarded assessment.

Analysis Checks(5/10)

Revenue-MV

Value0.73

Score2/3

Weight12.97%

1M Return3.89%

Net cash flow from operating activities per share (YoY growth rate %)

Value35.80

Score1/3

Weight6.34%

1M Return2.13%

Inventory turnover ratio

Value106.57

Score1/3

Weight4.79%

1M Return1.74%

Net income-Revenue

Value-0.63

Score2/3

Weight15.88%

1M Return4.82%

Basic earnings per share (YoY growth rate %)

Value265.55

Score3/3

Weight20.32%

1M Return6.64%

Total profit (YoY growth rate %)

Value313.57

Score3/3

Weight17.92%

1M Return5.90%

Net cash flow from operating activities (YoY growth rate %)

Value31.23

Score1/3

Weight4.75%

1M Return1.69%

Cash-UP

Value-0.36

Score1/3

Weight2.12%

1M Return0.84%

Diluted earnings per share (YoY growth rate %)

Value263.03

Score3/3

Weight20.88%

1M Return6.86%

Cash-MV

Value0.72

Score0/3

Weight-5.96%

1M Return-2.55%

Is MD undervalued or overvalued?

MD scores 5.52/10 on fundamentals and holds a Fair valuation at present. Backed by its 20.28% ROE, 8.64% net margin, 10.54 P/E ratio, 2.01 P/B ratio, and 265.55% earnings growth, these metrics solidify its Netural investment rating.